Dr. Fidler on Balancing Benefit of Novel Agents in EGFR Exon 20–Mutant NSCLC With Toxicities


Mary Jo J. Fidler, MD, discusses the potential for novel agents in EGFR exon 20–mutated non–small cell lung cancer.

Mary Jo J. Fidler, MD, an associate professor in the Department of Internal Medicine, Division of Hematology, Oncology and Cell Therapy at Rush Medical College, Rush University Medical Center, discusses the potential for novel agents in EGFR exon 20–mutated non–small cell lung cancer (NSCLC).

Encouraging signals have been observed with novel agents like mobocertinib (formerly TAK-788), when used in this patient population, despite toxicity challenges, Fidler says. However, there is optimism that progress will be made with EGFR inhibitors for this patient population, Fidler adds.

To accomplish more with these agents, it is important that the associated toxicity is effectively managed, Fidler says. More impact may be achieved by designing newer agents, schedules, or combinations for use in patients with EGFR exon 20–mutant NSCLC, Fidler concludes.

Related Videos
Jobelle Baldonado, MD
Joshua K. Sabari, MD, an expert on lung cancer, presenting slides
Chul Kim, MD, MPH
Salman R. Punekar, MD, Mayo Clinic
Federico Cappuzzo, MD
Pasi A. Jänne, MD, PhD, director, Lowe Center for Thoracic Oncology, director, Belfer Center for Applied Cancer Science, director, Chen-Huang Center for EGFR Mutant Lung Cancers, senior physician, David M. Livingston, MD, Chair, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Edgardo S. Santos Castillero, MD, FACP
Joshua K. Sabari, MD